Christopher Jones, MD
Internal Medicine · Murray, UTNPI 1417967837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 98.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $390 and has fallen 57.8% since, to $164 in 2024.
Across 108 payments — averaging $7.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$823
- BETA Bionics, Inc.$16
What the payments were for
- Food & beverage$839100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 107 | $823 |
| BETA Bionics, Inc. | 1 | $16 |
How this compares
$839 in reported general payments places this provider in the 70th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 146 | $199,380 |
| MounjaroTirzepatide | 89 | $110,932 |
| OzempicSemaglutide | 62 | $95,549 |
| TrulicityDulaglutide | 66 | $89,625 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $54,140 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $52,615 |
| FarxigaDapagliflozin Propanediol | 47 | $40,596 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $37,851 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $32,929 |
| TradjentaLinagliptin | 36 | $32,597 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $27,673 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 120 | $22,673 |
| RybelsusSemaglutide | 11 | $19,943 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $16,337 |
| Novolog FlexpenInsulin Aspart | 33 | $15,152 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Murray
- Steven JepsonMurray$7K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
- Barbara RizzardiSandy$30K
- Gerald GleichSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.